It is important to note than in this study, although high PSMA uptake was noted both on [68Ga]Ga-PSMA-11 PET CT and post-therapeutic images, retention times and tumor doses were lower and shorter than in prostate cancer, probably explaining the reduced effectiveness of the treatment compared to the VISION trial. The gene discussed is FOLH1; the disease is prostate cancer.